文献速递临床试验与 GCP基础与转化研究

两种无创呼吸支持疗法(持续气道正压通气与经鼻高流量氧疗)在急性呼吸窘迫综合征患者中的生理学效应:随机临床试验研究方案

Physiologic effects of two non-invasive respiratory support therapies (continuous positive airway pressure versus high-flow nasal oxygenation) in patients with acute respiratory distress syndrome: study protocol for a randomized clinical trial.
PubMed 文献 · Trials · 2026-01-02

本研究为多中心、随机、开放标签、对照试验,计划纳入120例未插管的急性呼吸窘迫综合征(ARDS)患者,随机接受持续气道正压通气(CPAP)12 cmH2O或经鼻高流量氧疗(HFNO)50 L/min治疗48小时,主要结局为血浆可溶性晚期糖基化终末产物受体(sRAGE)水平反映的生物性肺损伤,次要结局包括肺应变、摆动呼吸、跨肺压等患者自致肺损伤(P-SILI)效应指标及48小时、90天气管插管率和90天死亡率。

要点

  • 120例未插管ARDS患者随机接受CPAP 12 cmH2O或HFNO 50 L/min治疗48小时。
  • 主要结局为血浆sRAGE水平反映的生物性肺损伤。
  • 次要结局包括P-SILI效应指标、48小时及90天气管插管率和90天死亡率。

核心结论

  • 本研究将评估CPAP相比HFNO在减轻P-SILI效应和生物性肺损伤方面的潜在作用,这一生理学效应可能带来更低的气管插管率和死亡率。

研究设计与样本

  • 多中心、随机、开放标签、对照试验,计划纳入120例已确诊ARDS的未插管患者,随机接受CPAP 12 cmH2O或HFNO 50 L/min治疗48小时,全部分析按意向性治疗原则进行。

主要发现

  • 主要结局为血浆可溶性晚期糖基化终末产物受体(sRAGE)水平评估的生物性肺损伤;次要结局包括血浆肺功能障碍生物标志物、P-SILI效应指标(肺应变、摆动呼吸、跨肺压)、48小时气管插管率、90天气管插管率和90天死亡率。

关键数值与推荐

  • CPAP组参数为12 cmH2O,HFNO组参数为50 L/min,干预时长均为48小时。

临床怎么用

  • 作者认为该生理学效应可能带来更低的气管插管率和死亡率,并将为未插管ARDS患者的呼吸管理提供缺乏的证据。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute respiratory distress syndrome (ARDS) is the acute hypoxemic respiratory failure that presents with non-cardiogenic pulmonary opacities. Patients receiving non-invasive respiratory support might present with high transpulmonary pressure, pulmonary strain, and pendelluft, which contribute to the development of patient self-inflicted lung injury (P-SILI). Experimental studies have identified that continuous positive airway pressure (CPAP) is successful in attenuating P-SILI effectors compared to high-flow nasal oxygenation (HFNO). However, it remains uncertain whether this attenuation is associated with a reduction in lung injury and improved clinical outcomes. METHODS: This is a multicenter, randomized, open-label, controlled trial. One hundred and twenty non-intubated patients with established ARDS will be randomly assigned to receive non-invasive respiratory support with either CPAP 12 cmH2O or HFNO 50 L/min for 48 h. The primary outcome is biological lung injury, assessed with plasma levels of the epithelial pulmonary dysfunction biomarker sRAGE (soluble Receptor of Advanced Glycation End-products). Secondary outcomes include plasmatic pulmonary dysfunction biomarkers, P-SILI effectors (pulmonary strain, pendelluft, transpulmonary pressure), 48-h tracheal intubation rate, 90-day tracheal intubation rate, and 90-day mortality. All analyses will be conducted according to the intention-to-treat principle. DISCUSSION: This study will assess the potential role of CPAP in attenuating P-SILI effectors and inflicting less biological lung injury compared to HFNO. This physiologic effect may lead to lower rates of tracheal intubation and mortality. This project will provide new knowledge on the respiratory management of non-intubated ARDS patients, a subject where evidence is lacking. TRIAL REGISTRATION: ClinicalTrials.gov NCT06694311. Registered on 18 November 2024 as HCB/2023/1105.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Vallverdú J, Barbeta E, Mellado R, et al. Physiologic effects of two non-invasive respiratory support therapies (continuous positive airway pressure versus high-flow nasal oxygenation) in patients with acute respiratory distress syndrome: study protocol for a randomized clinical trial. Trials. 2026. PMID: 41484920. doi:10.1186/s13063-025-09344-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。